Pcsk9 inhibitors long-term side effects
Pro Research Analysisby 
Searched over 200M research papers
Long-Term Side Effects of PCSK9 Inhibitors
Introduction to PCSK9 Inhibitors
PCSK9 inhibitors are a class of drugs that have shown significant promise in lowering low-density lipoprotein (LDL) cholesterol levels, thereby reducing the risk of cardiovascular diseases. These inhibitors work by upregulating LDL receptor availability, which enhances the clearance of LDL cholesterol from the bloodstream 39. Despite their efficacy, the long-term safety profile of PCSK9 inhibitors remains a topic of ongoing research and debate.
Increased Risk of Type 2 Diabetes
One of the most concerning potential long-term side effects of PCSK9 inhibitors is an increased risk of type 2 diabetes mellitus (T2DM). Genetic studies have shown that variants in the PCSK9 gene associated with lower LDL levels are also linked to a higher risk of T2DM . This association has been supported by meta-analyses of clinical trials, which indicate that PCSK9 inhibitors can lead to small but significant increases in fasting blood glucose and HbA1c levels, although this does not necessarily translate into a higher incidence of diabetes .
Neurocognitive Adverse Events
Neurocognitive side effects are another area of concern. Some studies have suggested that PCSK9 inhibitors may be associated with an increased risk of neurocognitive adverse events, such as memory loss and confusion 59. However, these events are relatively rare and have not been consistently linked to the levels of LDL cholesterol achieved during treatment. The U.S. Food and Drug Administration (FDA) has recommended close monitoring of neurocognitive effects in ongoing and future trials .
Musculoskeletal and Other Adverse Events
Musculoskeletal pain and other mild to moderate adverse events, such as cough, nasopharyngitis, headache, back pain, and diarrhea, have been reported in clinical trials . However, these events are generally not severe and do not lead to discontinuation of the therapy. Meta-analyses have shown no significant difference in the incidence of serious adverse events or musculoskeletal issues between PCSK9 inhibitors and control treatments 57.
Potential for Other Health Issues
Genetic assessments have also indicated potential associations between PCSK9 inhibition and other health issues, such as increased body mass index, waist circumference, and diastolic blood pressure. There are also nominally significant associations with conditions like peptic ulcer disease, depression, asthma, chronic kidney disease, and venous thromboembolism . However, these findings are preliminary and require further investigation.
Conclusion
While PCSK9 inhibitors are effective in lowering LDL cholesterol and reducing cardiovascular risk, their long-term safety profile is still being elucidated. Current evidence suggests a potential increased risk of type 2 diabetes and neurocognitive adverse events, although these risks appear to be relatively low. Ongoing and future studies will be crucial in fully understanding the long-term side effects of these promising drugs. Close monitoring and further research are essential to ensure their safe and effective use in clinical practice.
Sources and full results
Most relevant research papers on this topic